2023 Compliance and Policy Report

Medicare MolDX Working to Streamline Policies, Speed Assessments

Top Compliance Challenges for Clinical Laboratories

Payment Coverage Key Policy Concerns for MAWD Pathology

FDA to Move Forward on LDT Rulemaking

OIG Targets Drug Testing Overpayments for G0483

EKRA Rulings Cause Confusion, Clarification Needed

CMS Says Its Policy Already Allows Nurses to Perform Moderate and High-Complexity Testing

Tips on Assessing, Mitigating Compliance Risk Under EKRA

OIG Clarifies Use of Gift Cards to Encourage Screening Tests

How to Ace Your Lab’s Competency Assessments

Top Five Lab Billing and Coding Changes

National Diagnostics Action Plan Proposes Solution for Future Pandemics

FDA Preparing to Issue Proposed Rule on LDT Oversight

Key Legal Hotspots for Laboratory Sales Reps: Tips on What NOT to Do

Q&A With Gregg Brandush, CMS Division of Clinical Laboratory Improvement and Quality

FTC Takes First-of-Its-Kind Action Against Genetic Testing Company

Labs, Path Groups Should Review Restrictive Covenants in Anticipation of Non-compete Ban

Pathologists Face Medicare Cuts in 2024 Under Proposed Rule

Warren Investigating Google Efforts to Monetize Military Tissue Samples

Navigating New CMS Billing Edits for Drug Testing

Pathologists Call for Changes to Palmetto Special Stains Policy

Some MACs Changing Coding on STI Testing in Conflict

MolDX to Cover Molecular Biomaker Testing for RA Targeted Therapy Selection

Labor Departments Sues United Subsidiary Over Denied Drug Screening Claims

HHS OIG Nixes AP Purchased Services Agreement

FDA Tries Once Again to Regulate LDTs, Lab Groups Push Back

PathAI Announces 13 Lab Contracts for Its AI Tools

New OIG Compliance Guidance Places Emphasis on Individual Risk Assessment

Best Practices for Specialty Labs Contracting for Specimen Collection

What’s on the Government’s Radar for Labs in 2024?